It remains a bona fide mystery of the microbiome drug development field: Why did the most advanced drug in this promising corner of the life sciences have such a spectacular trial failure in treating a disease widely thought to be a relatively easy target?
Lots of speculation has been floated in the past two weeks on the possible reasons that Cambridge-based Seres Therapeutics (Nasdaq: MCRB) reported disappointing interim results from a mid-stage study of SER-109 in patients with recurrent Clostridium…
It remains a bona fide mystery of the microbiome drug development field: Why did the most advanced drug in this promising corner of the life sciences have such a spectacular trial failure in treating a disease widely thought to be a relatively easy target?
Lots of speculation has been floated in the past two weeks on the possible reasons that Cambridge-based Seres Therapeutics (Nasdaq: MCRB) reported disappointing interim results from a mid-stage study of SER-109 in patients with recurrent Clostridium…